Treatment of Type 2 Diabetes With Linagliptin 2.5 mg Bid + Metformin 500 or 1000 mg Bid and Metformin 1000 mg Bid
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
A phase III randomised, double-blind parallel group extension study to investigate the
efficacy and safety of twice daily administration of the free combination of linagliptin 2.5
mg + metformin 500 mg or of linagliptin 2.5 mg + metformin 1000 mg versus monotherapy with
metformin 1000 mg twice daily over 54 weeks in type 2 diabetic patients previously completing
the double-blind part of study 1218.46